Emilie Auditeau1, Luz Maria Moyano2, Geneviève Bourdy3, Mandy Nizard4, Jérémy Jost5, Voa Ratsimbazafy6, Pierre-Marie Preux7, Farid Boumediene8. 1. INSERM, U1094, Tropical Neuroepidemiology, 2 rue du Dr Marcland, 87025 Limoges, France; Univ. Limoges, UMR 1094, Tropical Neuroepidemiology, Institute of Neuroepidemiology and Tropical Neurology, 2 rue du Dr Marcland, 87025 Limoges, France. Electronic address: emilie.auditeau@gmail.com. 2. INSERM, U1094, Tropical Neuroepidemiology, 2 rue du Dr Marcland, 87025 Limoges, France; Univ. Limoges, UMR 1094, Tropical Neuroepidemiology, Institute of Neuroepidemiology and Tropical Neurology, 2 rue du Dr Marcland, 87025 Limoges, France; Cysticercosis Elimination Program and Center for Global Health Tumbes, University Peruana Cayetano Heredia, Avenida Panamericana Norte, Tumbes, Peru. Electronic address: luzmariamoyano@gmail.com. 3. UMR 152 Research Institute for the development, University Toulouse 3, Pharmaceutical sciences Faculty, 35 chemin des Maraîchers, 31400 Toulouse, France. Electronic address: bourdygenevieve@yahoo.fr. 4. INSERM, U1094, Tropical Neuroepidemiology, 2 rue du Dr Marcland, 87025 Limoges, France; Univ. Limoges, UMR 1094, Tropical Neuroepidemiology, Institute of Neuroepidemiology and Tropical Neurology, 2 rue du Dr Marcland, 87025 Limoges, France. Electronic address: mandy.nizard@gmail.com. 5. INSERM, U1094, Tropical Neuroepidemiology, 2 rue du Dr Marcland, 87025 Limoges, France; Univ. Limoges, UMR 1094, Tropical Neuroepidemiology, Institute of Neuroepidemiology and Tropical Neurology, 2 rue du Dr Marcland, 87025 Limoges, France. Electronic address: Jeremy.Jost@chu-limoges.fr. 6. INSERM, U1094, Tropical Neuroepidemiology, 2 rue du Dr Marcland, 87025 Limoges, France; Univ. Limoges, UMR 1094, Tropical Neuroepidemiology, Institute of Neuroepidemiology and Tropical Neurology, 2 rue du Dr Marcland, 87025 Limoges, France. Electronic address: voa_ratsimbazafy@yahoo.fr. 7. INSERM, U1094, Tropical Neuroepidemiology, 2 rue du Dr Marcland, 87025 Limoges, France; Univ. Limoges, UMR 1094, Tropical Neuroepidemiology, Institute of Neuroepidemiology and Tropical Neurology, 2 rue du Dr Marcland, 87025 Limoges, France. Electronic address: pierre-marie.preux@unilim.fr. 8. INSERM, U1094, Tropical Neuroepidemiology, 2 rue du Dr Marcland, 87025 Limoges, France; Univ. Limoges, UMR 1094, Tropical Neuroepidemiology, Institute of Neuroepidemiology and Tropical Neurology, 2 rue du Dr Marcland, 87025 Limoges, France. Electronic address: farid.boumediene@unilim.fr.
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE: Epilepsy affects 150,000 people in Peru, with a prevalence of 16.6/1000 and a treatment gap of 75%. Herbal medicine (HM) is widely used in this country. AIM OF THE STUDY: We aimed to assess the use of plants in a rural community in northern Peru as part of therapeutic strategies for people with epilepsy (PWE). MATERIALS AND METHODS: The study was a cross-sectional observational and descriptive study. The inclusion criteria for people with epilepsy were 2 years of age and over, having lived in the study area for at least 3 months and a confirmed diagnosis of epilepsy by a neurologist. The information was gathered through structured interviews using a survey questionnaire. Botanical species used by people with epilepsy or traditional healers were collected and identified. RESULTS: Out of the 228 people with epilepsy included, 60.0% had used herbal remedies and 54.8% both herbal medicine and anti-epileptic drugs. The traditional healer was the first practitioner consulted by 45.2% of people with epilepsy. Sixty-six species have been mentioned by the people with epilepsy and traditional healers on the treatment of epilepsy. Carbamazepine was the most prescribed anti-epileptic drug with 33.2% of prescriptions. CONCLUSIONS: This study was the first to measure a percentage of use of herbal medicine for epilepsy in Peru. It would be interesting to conduct a pharmacological evaluation of the most commonly used species on epileptic models to validate and secure their use.
ETHNOPHARMACOLOGICAL RELEVANCE: Epilepsy affects 150,000 people in Peru, with a prevalence of 16.6/1000 and a treatment gap of 75%. Herbal medicine (HM) is widely used in this country. AIM OF THE STUDY: We aimed to assess the use of plants in a rural community in northern Peru as part of therapeutic strategies for people with epilepsy (PWE). MATERIALS AND METHODS: The study was a cross-sectional observational and descriptive study. The inclusion criteria for people with epilepsy were 2 years of age and over, having lived in the study area for at least 3 months and a confirmed diagnosis of epilepsy by a neurologist. The information was gathered through structured interviews using a survey questionnaire. Botanical species used by people with epilepsy or traditional healers were collected and identified. RESULTS: Out of the 228 people with epilepsy included, 60.0% had used herbal remedies and 54.8% both herbal medicine and anti-epileptic drugs. The traditional healer was the first practitioner consulted by 45.2% of people with epilepsy. Sixty-six species have been mentioned by the people with epilepsy and traditional healers on the treatment of epilepsy. Carbamazepine was the most prescribed anti-epileptic drug with 33.2% of prescriptions. CONCLUSIONS: This study was the first to measure a percentage of use of herbal medicine for epilepsy in Peru. It would be interesting to conduct a pharmacological evaluation of the most commonly used species on epileptic models to validate and secure their use.
Keywords:
Botany; Central nervous system; Epilepsy; Medicinal plants; Peru; Quality traditional medicines; Therapeutic strategy; Traditional medicine Meso- and Southern America; WHO Traditional Medicine Strategy
Authors: Mary C Spiciarich; Jane R von Gaudecker; Laura Jurasek; Dave F Clarke; Jorge Burneo; Jorge Vidaurre Journal: Curr Neurol Neurosci Rep Date: 2019-05-01 Impact factor: 5.081
Authors: Gabrielle Bonnet; Francesco Pizzitutti; Eloy A Gonzales-Gustavson; Sarah Gabriël; William K Pan; Hector H Garcia; Javier A Bustos; Percy Vilchez; Seth E O'Neal Journal: PLoS Comput Biol Date: 2022-05-19 Impact factor: 4.779
Authors: Luz M Moyano; Silvia M Montano; Percy Vilchez Barreto; Narcisa Reto; Luis Larrauri; Nicanor Mori; Mario Cornejo-Olivas; Erik Guevara-Silva; Fernando Urizar; Enrique Najar; Ricardo Gamboa; Cintya Azabache; Raquel Herrer Ticse; Lucia Bolivar-Herrada; Alex Doud; Peggy Martinez; J Jaime Miranda; Joseph R Zunt; Hector H García Journal: PLoS One Date: 2021-07-29 Impact factor: 3.240